534 related articles for article (PubMed ID: 19508916)
21. Unmet needs in modern vaccinology: adjuvants to improve the immune response.
Leroux-Roels G
Vaccine; 2010 Aug; 28 Suppl 3():C25-36. PubMed ID: 20713254
[TBL] [Abstract][Full Text] [Related]
22. IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems.
Lingnau K; Riedl K; von Gabain A
Expert Rev Vaccines; 2007 Oct; 6(5):741-6. PubMed ID: 17931154
[TBL] [Abstract][Full Text] [Related]
23. Cationic liposomes as vaccine adjuvants.
Christensen D; Korsholm KS; Andersen P; Agger EM
Expert Rev Vaccines; 2011 Apr; 10(4):513-21. PubMed ID: 21506648
[TBL] [Abstract][Full Text] [Related]
24. New horizons in adjuvants for vaccine development.
Reed SG; Bertholet S; Coler RN; Friede M
Trends Immunol; 2009 Jan; 30(1):23-32. PubMed ID: 19059004
[TBL] [Abstract][Full Text] [Related]
25. Microparticle-based technologies for vaccines.
O'Hagan DT; Singh M; Ulmer JB
Methods; 2006 Sep; 40(1):10-9. PubMed ID: 16997709
[TBL] [Abstract][Full Text] [Related]
26. Advances in vaccine adjuvants.
Singh M; O'Hagan D
Nat Biotechnol; 1999 Nov; 17(11):1075-81. PubMed ID: 10545912
[TBL] [Abstract][Full Text] [Related]
27. Biomaterials as vaccine adjuvants.
Jones KS
Biotechnol Prog; 2008; 24(4):807-14. PubMed ID: 19194892
[TBL] [Abstract][Full Text] [Related]
28. Bioadhesive delivery systems for mucosal vaccine delivery.
Baudner BC; O'Hagan DT
J Drug Target; 2010 Dec; 18(10):752-70. PubMed ID: 21039314
[TBL] [Abstract][Full Text] [Related]
29. Improving vaccine performance with adjuvants.
Vogel FR
Clin Infect Dis; 2000 Jun; 30 Suppl 3():S266-70. PubMed ID: 10875797
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood.
Laupèze B; Hervé C; Di Pasquale A; Tavares Da Silva F
Vaccine; 2019 Sep; 37(38):5670-5680. PubMed ID: 31420171
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations.
Tomljenovic L; Shaw CA
Lupus; 2012 Feb; 21(2):223-30. PubMed ID: 22235057
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in vaccine adjuvants.
Singh M; O'Hagan DT
Pharm Res; 2002 Jun; 19(6):715-28. PubMed ID: 12134940
[TBL] [Abstract][Full Text] [Related]
33. Liposomal vaccine delivery systems.
Henriksen-Lacey M; Korsholm KS; Andersen P; Perrie Y; Christensen D
Expert Opin Drug Deliv; 2011 Apr; 8(4):505-19. PubMed ID: 21413904
[TBL] [Abstract][Full Text] [Related]
34. Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies.
Brennan FR; Dougan G
Vaccine; 2005 May; 23(24):3210-22. PubMed ID: 15837222
[TBL] [Abstract][Full Text] [Related]
35. Vaccine adjuvant safety: the elephant in the room.
Petrovsky N
Expert Rev Vaccines; 2013 Jul; 12(7):715-7. PubMed ID: 23885815
[No Abstract] [Full Text] [Related]
36. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines.
Baldridge JR; Crane RT
Methods; 1999 Sep; 19(1):103-7. PubMed ID: 10525445
[TBL] [Abstract][Full Text] [Related]
37. Advances in transcutaneous vaccine delivery: do all ways lead to Rome?
Bal SM; Ding Z; van Riet E; Jiskoot W; Bouwstra JA
J Control Release; 2010 Dec; 148(3):266-82. PubMed ID: 20869998
[TBL] [Abstract][Full Text] [Related]
38. Innate immunity and new adjuvants.
Mutwiri G; Gerdts V; Lopez M; Babiuk LA
Rev Sci Tech; 2007 Apr; 26(1):147-56. PubMed ID: 17633299
[TBL] [Abstract][Full Text] [Related]
39. Nasal vaccine innovation.
Jabbal-Gill I
J Drug Target; 2010 Dec; 18(10):771-86. PubMed ID: 21047271
[TBL] [Abstract][Full Text] [Related]
40. Adjuvants for malaria vaccines.
Coler RN; Carter D; Friede M; Reed SG
Parasite Immunol; 2009 Sep; 31(9):520-8. PubMed ID: 19691556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
